Summary

A once-daily inhaled dual bronchodilator consisting of a long-acting β2-agonist and a long-acting muscarinic antagonist significantly improved self-reported shortness of breath and lung function compared with placebo and tiotropium in patients with moderate to severe chronic obstructive pulmonary disease. This article discusses results of the Effect of QVA149 on Dyspnea in Patients With Chronic Obstructive Pulmonary Disease study [BLAZE; NCT01490125], a multicenter, randomized, blinded, double-dummy, placebo-controlled, 3-period, crossover trial.